Deliver
“medicines that matter”
for patients

previous arrowprevious arrow
next arrownext arrow
Slider

Mission

Deliver “medicines that matter” to improve patient health and contribute to enhanced quality of life. At ARTham Therapeutics, we will create value by developing innovative medicines that are disease modifying and improve patient health.

Value

ARTham Therapeutics Inc., is a clinical stage biopharmaceutical company that will deliver ‘medicines that matter’ for patients. Our goal is to create innovative medicines that are disease modifying and satisfy significant unmet medical need. To deliver on cost and time efficiency, ARTham will run a virtual R&D operating model that seeks innovation through the best academic and business partners.

Teams

  • Management team
  • Scientific Leadership
  • Directors
  • Investors

Management team

Hiroshi Nagabukuro
Ph.D.

CEO

Read more

Hiroshi Nagabukuro , Ph.D.

CEO
Adjunct Professor, Oita University
Visiting fellow, Yokohama City University
Former Sr Director, Innovation & Entrepreneurship, Extra Value Generation Drug Discovery Unit,
Takeda Pharmaceuticals.; Research Fellow, Merck Research Labs, USA; Visiting Fellow, Florida State University
Expert in pharmacology, translational medicine, drug repositioning

Sham Nikam
Ph.D.

Chief Strategy Officer

Read more

Sham Nikam , Ph.D.

Chief Strategy Officer
Former VP, Head of Innovation & Entrepreneurship,Extra Value Generation Drug
Discovery Unit, Takeda Pharmaceuticals;
Global Head of Discovery, Nycomed, Zurich;
Director, Chemistry & Neuroscience
Therapeutic Area, Parke-Davis/Warner Lambert and Pfizer; Smith Kline & French Labs (now GSK), Sandoz (now Novartis); Adjunct Associate Professor, University of Michigan, Ann Arbor
Expert in drug discovery/early development
medicinal chemistry, CMC, informatics, drug repositioning

Naoto Uemura
M.D., Ph.D.

Chief Medical Advisor

Read more

Naoto Uemura , M.D., Ph.D.

Chief Medical Advisor
Professor, Clinical Pharmacology, Oita University;
Adjunct Professor, Osaka University
Former Director and International Fellow, Clinical Research, Merck Research Labs, USA;
Visiting Research Scholar University of California at San Francisco (UCSF)
Expert in clinical pharmacology, translational medicine,
early clinical development

Scientific Leadership

Akira Tanaka
Ph.D.

Vice President
Clinical Science

Read more

Akira Tanaka , Ph.D.

Vice President
Clinical Science
Adjunct Assistant Professor, Oita University
Former Clinical Scientist, Takeda Gastrointestinal Therapeutic Area Unit, Boston, USA; Principal Scientist, Extra Value Generation Drug Discovery Unit, Oncology Drug Discovery Unit, Takeda Pharmaceuticals
Expert in clinical science, pharmacology, endocrinology, oncology, drug repositioning

Kanako Kuniyeda
Ph.D.

Director
Discovery Science

Read more

Kanako Kuniyeda , Ph.D.

Director
Discovery Science
Adjunct Assistant Professor, Oita University
Former Principal Scientist, Innovative Biology Labs, Extra Value Generation Drug Discovery Unit, Takeda Pharmaceuticals
Expert in biochemistry, molecular biology, drug repositioning

Haruhi Kamisaki Ando
Ph.D.

Associate Director
Clinical Science

Read more

Haruhi Kamisaki Ando , Ph.D.

Associate Director
Clinical Science
Adjunct Assistant Professor, Oita University
Former Clinical Research Associate, Medical Writing, PRA health sciences; Medicinal Chemist, Medicinal Chemistry Labs, CNS Drug Discovery Unit, CVM Drug Discovery Unit, Takeda Pharmaceuticals.
Expert in medicinal chemistry, organic synthesis chemistry, transition metal chemistry

Directors

Hiroshi Nagabukuro

CEO

Read more

Sham Nikam

Chief Strategy Officer

Read more

Hiroyuki Misawa

Partner at Miyako Capital

Taro Tokita

Audit and Supervisory Board Member

Investors

  • Other:Takeda Pharmaceutical Company Limited

Unravel hidden value
and deliver drugs that
ultimately help patients

Science

  • Pipline
  • ART-648
  • ART-001
  • ART-002

Pipline

ART-648

Orally available phosphodiesterase type 4 (PDE4) inhibitor

  • Broad spectrum anti-inflammatory effects via intracellular cAMP increase
  • Preclinical validation of anti-fibrotic and anti-obesity effects
  • Opportunities to treat dermal (bullous pemphigoid, psoriatic arthritis),
    metabolic (NASH) and respiratory (COPD, IPF) disorders with high unmet medical needs
  • Optimal pharmacokinetic and safety/tolerability profile demonstrated in Phase 1 clinical study in healthy subjects

Indication: Bullous Pemphigoid

  • A rare autoimmune chronic skin disorder resulting in generalized, pruritic, bullous lesions
  • Autoantibodies recognize components of the basement membrane zone called BP180 and BP230
  • Primarily a geriatric dermal disorder that occurs in patients aged >70 years
  • Usually starts with redness and itching of the skin, and within weeks to months, thin-walled, tense blisters appear
    over whole body
  • Mucous membranes may also be involved, but less common
  • Topical and systemic corticosteroids as standard cares for patients with moderate-severe conditions
  • Prevalence in the US: 12 /100,000 adults; 38/100,000 adults aged ≥60 years (Wertenteil et al., 2018)
  • ~7,000 patients in Japan (Japan Intractable Diseases Information Center); ~20,000 patients including patients with mild symptoms
  • R&D grant from the Japan Agency for Medical Research and Development (AMED) Program for Orphan Drugs prior
    to Designation awarded since FY2020
  • Phase 2 study to be initiated in 1H FY2021 (Japan Fiscal Year: April 1st to March 31st)

Indication: COVID-19

  • Potential novel pharmacotherapy to prevent developing severe pneumonia in COVID-19 patients with
    mild to moderate conditions and long term lung tissue damage leading to fibrosis
  • Prevent cytokine storm by anti-inflammatory effects via various types of inflammatory and immune cells
  • Active collaboration with National Center for Global Health & Medicine, Timewell Medical Inc., and Oita University
  • AMED R&D grant awarded since FY2020
  • Phase 2 study to be initiated in 1H FY2021

ART-001

New Effective Treatment for Vascular Malformations

ART-001: First in Class PI3K (phosphatidylinositol-3-kinase) inhibitor for
the treatment of vascular malformations and overgrowth syndromes

  • Significant unmet medical need with no current pharmacotherapy
  • Patient with GOF mutation of PI3K-AKT pathway
  • Selective inhibition of angiogenesis
  • This program has received a grant from AMED, Japanese Agency for Medical Research and Development.

Vascular malformations are benign (non-cancerous) lesions that are present at birth,
but may become visible for weeks or months after birth. Unlike hemangiomas, vascular malformations
do not have a growth cycle and then regress but instead continue to grow slowly throughout life.
Most vascular malformations are sporadic (occurring by chance),
though some are inherited in a family as an autosomal dominant trait.

ART-002

under preparation

Access

From STASION

From Nihon-Odori Station on Minatomirai Line,
6 minute walk from Exit 3.

24-8, Yamashita-cho, Naka-ku, Yokohama
Kanagawa 231-0023, Japan
Phone :
+81-45-225-8858